Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-selected therapies after chemoradiotherapy for unresectable stage III NSCLC
2023-503920-14-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised trial of durvalumab and alectinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Roche. Primary endpoint: Progression-free survival (PFS) by BICR. Planned start Feb 2024; status: authorised.
02
Drugs
durvalumabalectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503920-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503920-14-00.